Literature DB >> 17544960

Deep morphea.

Isabel Bielsa1, Aurelio Ariza.   

Abstract

Deep morphea encompasses a variety of clinical entities in which inflammation and sclerosis are found in the deep dermis, panniculus, fascia, or superficial muscle. Morphea profunda, eosinophilic fasciitis, and disabling pansclerotic morphea of children are included in this group, but overlapping of the extent and depth of cutaneous involvement in these various conditions precludes their distinction on the sole basis of clinical or even histologic examination. Furthermore, the limits between morphea profunda and generalized morphea, which usually are classified outside this group, are not clear. Histologically, all these disorders show similar inflammatory and sclerotic findings, the primary difference being the depth of these changes. Associated clinical findings, including arthralgias, arthritis, contractures, or carpal tunnel syndrome, are frequent. Although visceral complications are uncommon, pulmonary, esophageal, and even cardiac abnormalities have been reported. Eosinophilia, hypergammaglobulinemia, and increased erythrocyte sedimentation rate may be present with disease activity. Laboratory studies may demonstrate autoantibody production. Treatment is nonstandardized but UVA irradiation and antiinflammatory or immunosuppressive drugs (mainly antimalarial agents and corticosteroids) may be beneficial.

Entities:  

Mesh:

Year:  2007        PMID: 17544960     DOI: 10.1016/j.sder.2007.02.005

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  13 in total

Review 1.  Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.

Authors:  Caterina Ferreli; Giulia Gasparini; Aurora Parodi; Emanuele Cozzani; Franco Rongioletti; Laura Atzori
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

2.  Pfeifer-Weber-Christian disease and successful treatment with mycophenolate mofetil: a case report.

Authors:  Subash Somalanka; Ini Udo; Hari Nair; Shashidhar Baikunje
Journal:  BMJ Case Rep       Date:  2019-05-22

3.  Update on management of connective tissue panniculitides.

Authors:  Inbal Braunstein; Victoria P Werth
Journal:  Dermatol Ther       Date:  2012 Mar-Apr       Impact factor: 2.851

4.  Association between quality of life and clinical characteristics in patients with morphea.

Authors:  G Bali; S Kárpáti; M Sárdy; V Brodszky; B Hidvégi; F Rencz
Journal:  Qual Life Res       Date:  2018-06-19       Impact factor: 4.147

5.  [Imaging of eosinophilic fasciitis in ultrasound and MRI (magnetic resonance imaging): a case report].

Authors:  Nicolas Gerritzen; Jana Ziob; Peter Brossart; Valentin S Schäfer
Journal:  Z Rheumatol       Date:  2022-05-16       Impact factor: 1.372

6.  Treatment of morphea with hydroxychloroquine: A retrospective review of 84 patients at Mayo Clinic, 1996-2013.

Authors:  Anagha Bangalore Kumar; Elizabeth K Blixt; Lisa A Drage; Rokea A El-Azhary; David A Wetter
Journal:  J Am Acad Dermatol       Date:  2019-01-29       Impact factor: 11.527

7.  Resolution of pansclerotic morphea after treatment with antithymocyte globulin.

Authors:  Philip Song; Christopher Gocke; Fredrick M Wigley; Francesco Boin
Journal:  Nat Rev Rheumatol       Date:  2009-09       Impact factor: 20.543

8.  Extracorporeal photochemotherapy for generalized deep morphea.

Authors:  Jason H Neustadter; Frank Samarin; Kacie R Carlson; Michael Girardi
Journal:  Arch Dermatol       Date:  2009-02

Review 9.  Scleroderma-like fibrosing disorders.

Authors:  Francesco Boin; Laura K Hummers
Journal:  Rheum Dis Clin North Am       Date:  2008-02       Impact factor: 2.670

10.  Extensive morphea profunda with autoantibodies and benign tumors: A rare case report.

Authors:  Leelavathy Budamakuntla; Dipali Malvankar
Journal:  Indian Dermatol Online J       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.